Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053 · View on ClinicalTrials.gov ↗

Study Summary

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.

Conditions Studied

Study Locations (20)

California

  • University of California - Irvine Medical Center — Irvine
  • Loma Linda Medical Center — Loma Linda
  • University of California - Los Angeles — Los Angeles
  • University of California - Davis — Sacramento
  • University of California - San Diego — San Diego
  • University of California - San Francisco — San Francisco

Illinois

  • Northwestern University — Chicago
  • University of Chicago — Chicago
  • Rush University Medical Center — Chicago
  • University of Illinois College of Medicine at Rockford — Rockford

Florida

  • University of Florida Board of Trustees — Gainesville
  • University of Miami — Miami
  • University of South Florida, HDSA Center of Excellence at USF — Tampa

Georgia

  • Emory University, Wesley Woods Health Center — Atlanta
  • Georgia Health Sciences University — Augusta

Alabama

  • University of Alabama — Birmingham

Arizona

  • St. Joseph's Hospital and Medical Center — Phoenix

Colorado

  • Cenexel Rocky Mountain Clinical Research, LLC — Englewood

Connecticut

  • University of Connecticut — Farmington

Trial Details

FieldValue
Enrollment Target 35,000 participants
Start Date 2012-07
Est. Completion 2062-01

Sponsor

CHDI Foundation

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01574053

The ClinicalTrials.gov registry entry for NCT01574053 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 35,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CHDI Foundation, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01574053 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Illinois, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01574053 about?

NCT01574053 is a clinical study titled "Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort". Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into...

What is the current status of trial NCT01574053?

This trial is currently recruiting. The enrollment target is 35,000 participants. The study started on 2012-07. Estimated completion is 2062-01.

What conditions does trial NCT01574053 study?

This clinical trial studies the following conditions: Huntington's Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT01574053?

This trial is sponsored by CHDI Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01574053 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial